LEGATO at the EU Cancer Mission’s 5th Anniversary Event: Stronger Through Connection
From 29 September to 1 October 2026, the LEGATO consortium was represented at “5 Years EU Cancer Mission:...
The LEGATO project is proposing an investigator-initiated phase III randomised pragmatic clinical trial.
Recurrent glioblastoma is an invariably fatal refractory cancer with dismal prognosis. Patients suffer from low quality of life and very burdensome symptoms.
Cost-effectiveness analysis will be performed to investigate the economic value of adding radiation treatment to lomustine chemotherapy.
We are a multidisciplinary and multistakeholder consortium involving clinical oncologists, radiation oncologists, health economists and patient representatives. The study design was successfully discussed with patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment.”
From 29 September to 1 October 2026, the LEGATO consortium was represented at “5 Years EU Cancer Mission:...
We would like to thank all the patients who have chosen to participate in this definitive study, as...
We’re excited to share a video featuring Professor Matthias Preusser, Principal Investigator and Co-Leader of LEGATO. Produced by...
© The LEGATO Consortium 2023-2028. This project has received funding from the European Union’s HORIZON-MISS-CANCER-2022-01 under grant agreement Nº (101103655). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
Copyright © 2025 All rights reserved.